BioSpace News Archive

This week, the German drug company announced that it is closing the doors to its ‘innovation hub’ in Mission Bay.

A sense of urgency, powerful science, relentless ingenuity, hope and trust drove the development of Pfizer and BioNTech’s mRNA vaccine during the height of the COVID-19 pandemic. As the crisis appears to lessen, Pfizer is preparing for the next pandemic.

Umoja Biopharma, Alentis Therapeutics, RayzeBio and Camp4 Therapeutics are ramping up on series funds.

The failure marks a setback in the hunt for means other than vaccines to provide protection against the novel coronavirus and its variants.

The company noted it would continue to assess the STAR study’s complete data set before confirming its future plans for clinical development of timrepigene emparvovec.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, announced that the first subject has been successfully dosed in a phase 2 clinical trial of IBI362, a glucagon-like peptide 1 receptor and glucagon receptor dual agonist in China.

Mont-Saint-Guibert, June 15, 2021 - Novadip Biosciences, a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs, announced positive final results from a Phase I study of its autologous cell-based product, NVD-001, in patients needing single-level spinal fusion.

Alentis Therapeutics, the Swiss biotech developing breakthrough treatments for fibrotic diseases, announced that it has raised USD67 million in a Series B financing round.

Tissue engineering refers to an interdisciplinary sphere that uses combination of life sciences and engineering.

As per a study by Fact.MR, the global intravenous solutions market is estimated to demonstrate a healthy growth for the forecast period 2021 to 2031.